Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant

NCT00354120 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

121

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloblastic Leukemia
Lymphoblastic Leukemia
Myelodysplasia
Chronic Myeloid Leukemia
Myelofibrosis
Lympho-proliferative Diseases

Interventions

DRUG: Alentuzumab
DRUG: Globulina antilinfocitaria

Sponsor

Gruppo Italiano Trapianto di Midollo Osseo